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Circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) are increasingly recognized for their
potential utility in disease monitoring and therapeutic targeting. The clinical application of CTC/DTC requires
better understanding of the biological mechanisms behind tumor dissemination, the survival of DTCs, and
their activation to aggressive growth from dormancy. Recent research using animal models of DTCs and
CTCs have provided novel insights into these processes. Here, we discuss these findings in the context of
results obtained from the clinical analyses of CTCs and DTCs, which demonstrate that the animal models
mimic, in many aspects, the complex situation in patients.Many cancer patients are diagnosed with early-stage cancer
with no clinical symptoms of metastasis but subsequently suc-
cumb to metastatic relapse. Circulating tumor cells (CTCs) in
the blood and disseminated tumor cells (DTCs) that have already
reached a secondary organ but have not yet grown to become
clinical overt metastasis are frequently detected in these patients
and have been linked to poor prognosis (Pantel and Brakenhoff,
2004). To exploit the window of opportunity for therapeutic inter-
vention between initial dissemination and eventual metastatic
recurrence, a better understanding of the biology and clinical
relevance of tumor dissemination is needed. In this review, we
will discuss novel insights into various aspects of tumor dissem-
ination as the result of convergence in experimental animal
model research and clinical analysis. These emerging themes
will guide future research on DTCs and CTCs in preclinical and
clinical settings, which may lead to effective therapeutic strate-
gies to prevent metastatic relapse.
The Temporal-Spatial Dynamics of Tumor Cell
Dissemination
In contrast to the traditional notion that metastasis is a late event
in tumor progression, increasing evidence suggests that tumor
cells can disseminate from the earliest preneoplastic lesions,
sometimes even before the formation of overt primary tumors
(Figure 1; Table 1). In genetically modified mouse models of
pancreatic cancer, preneoplastic tumor cells were found to un-
dergo epithelial-mesenchymal transition (EMT) and seed distant
organs before frank malignancy could be detected (Rhim et al.,
2012). Interestingly, induction of pancreatitis and other inflam-
mation-associated events increased the number of circulating
pancreatic cells. This observation in pancreatic cancer is consis-
tent with an earlier report using inducible expression of onco-
genes in mammary epithelial cells. Untransformed mammary
epithelial cells can survive as disseminated cells in the lung
and assume malignant growth upon oncogene activation (Pod-
sypanina et al., 2008). Consistent with animal model studies,
patients with benign inflammatory bowel diseases show already
circulating epithelial cells in their peripheral blood (Pantel et al.,2012). Analysis of human epidermal growth factor receptor 2
(HER-2) and PyMT transgenic mice and ductal carcinoma
in situ (DCIS) in breast cancer patients also showed early
dissemination of tumor cells and micrometastasis (Hu¨semann
et al., 2008). Although it is unclear yet whether DCIS patients
with DTCs have an increased risk of metastatic relapse, these
findings clearly show that tumor cells in these early-stage lesions
already have the capacity to survive in the blood circulation and
home to distant organs. Taken together, these studies suggest
that dissemination of epithelial cells can occur very early, even
in premalignant lesions. It is even possible that progression of
these cells may contribute to the development of cancer of
unknown primary, which occurs in 0.5% and 7% of all cancer
patients (van de Wouw et al., 2002). Long-term prospective
follow-up studies are required to determine the fate of these
disseminated cells in humans, possibly with the aid of next
generation sequencing to determine the lineage relationship
between disseminated cells and eventual malignancies.
The emerging concept of tumor self-seeding has also
extended our understanding of the pathological impact of tumor
dissemination. In addition to seeding distant metastasis, DTCs
are found to have enhanced malignant features and often return
to the primary tumors to accelerate their expansion (Kim et al.,
2009). It might be difficult to prove that such self-seeding
demonstrated in elegant mouse models also occurs in cancer
patients. However, the observation that the presence of DTCs
in bone marrow is correlated to the subsequent occurrence of
local relapse in breast cancer patients (Braun et al., 2005; Janni
et al., 2011) suggests that tumor cells may recirculate from a
distant site (i.e., bone marrow) back to the primary site to give
rise to recurrent tumors. Future studies comparing the genomes
of DTCs at primary diagnosis with those of tumor cells in local
relapse sites might reveal important clues to this open question.
Epithelial-Mesenchymal Plasticity in Tumor
Dissemination
EMT has been considered as a key event for the epithelial tumor
cells to lose polarity and cell-cell adhesions to initiate tumorCancer Cell 23, May 13, 2013 ª2013 Elsevier Inc. 573
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Figure 1. Schematic Representation of the Steps in the
Dissemination, Survival, and Expansion of Metastatic Tumor Cells
Under the influence of stromal cells in the primary tumor microenvironment,
tumor cells undergo EMT or use other means of invasion to escape from the
primary tumor (Friedl and Alexander, 2011). Platelets protect CTCs in circu-
lation and further stimulate EMT by TGF-b and NF-kB signaling. Tumor-
derived factors and exosomes mobilize bone marrow-derived cells to form
premetastatic niche to promote the seeding and expansion of metastasis.
Stromal component at the metastasis niches enhances tumor survival,
stemness, and immune evasion. CTCs derived from the primary tumor or
metastasis may engage in multidirectional seeding to the primary tumor or
other metastasis sites. Examples of genes mediating different steps of tumor
dissemination are listed in Table 1.
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eries of the link between EMT and stem cell properties in both
normal and cancerous cells provided an appealing model to
link two important enabling characteristics of tumor dissemina-
tion (Mani et al., 2008), although the separation of EMT and
cancer stem cell properties has also been observed in some
experimental models (Celia`-Terrassa et al., 2012; Ocan˜a et al.,
2012).
In carcinomas, EMT-related pathways are under strong influ-
ence by the surrounding microenvironment (Lo´pez-Novoa and
Nieto, 2009). An example of such an interaction is induction of
EMT in tumor cells driven by cancer associated-fibroblasts or
myeloid-derived suppressor cells, a heterogeneous population
of early myeloid progenitors, immature granulocytes, macro-
phages, and dendritic cells with the capacity to suppress anti-
tumor T cell responses (Giannoni et al., 2011; Toh et al., 2011),
whereas pericytes exert the opposite influence (Cooke et al.,574 Cancer Cell 23, May 13, 2013 ª2013 Elsevier Inc.2012). In general, inflammation appears to be a strong inducer
of EMT, and recent experimental studies indicated that inflam-
matory stroma might be even obligatory to activate EMT and
dissemination in pancreatic lesions (Rhim et al., 2012).
In addition to the well-established role in protecting CTCs from
mechanical and immune assaults during circulation, platelets
have recently been shown to induce EMT in CTCs via transform-
ing growth factor b (TGF-b) and nuclear factor kB (NF-kB)
signaling and prime tumor cells for subsequent metastasis
(Labelle et al., 2011). Moreover, platelets can also function as
adaptor cells, linking tumor cells to ‘‘nursing’’ CD11b+ macro-
phages, which results in the establishment of microclots that
protect CTCs in blood (Gil-Bernabe´ et al., 2012). These experi-
mental studies provide a possible explanation for the reduction
of metastatic relapses in breast cancer patients receiving
aspirin, which blocks platelet aggregation (Algra and Rothwell,
2012). Small clusters consisting of tumor cells and non-tumor
cells have also been detected in the peripheral blood of cancer
patients and are associated with an unfavorable outcome (Hou
et al., 2012), although the cellular composition of these clusters
is heterogeneous and still a subject of ongoing investigations.
The relevance of EMT in cancer patients has been a topic of
heated debate (Ledford, 2011). Expression of master regulators
of EMT, such as Twist1, Zeb1, Zeb2, SNAIL1, and SNAIL2/Slug
in primary tumors has been linked to increased risk of metastatic
relapse (De Craene and Berx, 2013). Moreover, several reports
on CTCs clearly indicated that EMT occurs on CTCs in breast
and prostate cancer patients and is linked to an unfavorable
outcome (Bednarz et al., 2010; Joosse et al., 2012). As a conse-
quence, many research groups are currently focusing on the
development of new assays and markers that are able to detect
CTCs with an EMT phenotype (Alix-Panabie`res et al., 2012).
EMT-related markers are frequently coexpressed with different
epithelial markers (Bednarz-Knoll et al., 2012; Yu et al., 2013),
which implies that a considerable pool of CTCs might indeed
exhibit a semimesenchymal phenotype. EMT-related markers
are also found in cytokeratin-negative cells (Bednarz-Knoll
et al., 2012; Gradilone et al., 2011) that lack expression of the
common leukocytes antigen CD45, suggesting that these cells
may represent CTCs that have undergone complete EMT.
Thus, most of the current CTC technologies based only on
epithelial markers might be ‘‘blind’’ to potentially the most
dangerous cancer cells present in the circulation. Nevertheless,
it is unknown how abundant might be the pools of CTCs under-
going partial or full EMT in humans, although some studies have
begun to address this issue (Armstrong et al., 2011). Mesen-
chymal CTCs have been correlated with disease progression
and resistance to chemotherapy (Mego et al., 2012; Yu et al.,
2013). A caveat has to be noted for all studies that do not use
confirmation of tumor cell identity by genomic markers, because
most markers for (semi)-mesenchymal CTCs are not tumor-spe-
cific but can be also expressed on blood cells or circulating
CD45-negative endothelial cells (Bednarz-Knoll et al., 2012).
Previously, the ability of cancer cells to undergo EMT has been
linked to their stemness (Mani et al., 2008). However, recent
experimental studies indicate that some tumor cell lines arrested
in a mesenchymal state are more invasive but are unable to form
overt metastasis (Celia`-Terrassa et al., 2012; Ocan˜a et al., 2012;
Tsai et al., 2012; Tsuji et al., 2008). Since the EMT state has been
Table 1. Representative Genes with Functional Roles in Different Steps of Tumor Dissemination
Gene(s) Function Reference
EMT and Invasion
TWIST1 promotes EMT by suppressing E-cadherin expression and inducing
invadopodia formation
(Eckert et al., 2011; Yang et al., 2004)
SNAIL1 promotes EMT and tumor recurrence (Moody et al., 2005)
SNAIL2 master regulator of EMT and mammary stem cell/breast cancer stem cell (Guo et al., 2012)
ZEB1/2 promotes EMT by repressing E-cadherin and miR-200 family expression
and by increasing tumor stemness
(Spaderna et al., 2008; Wellner et al., 2009)
FOXC2 promotes EMT and tumor metastasis (Mani et al., 2007)
Prrx1 promotes EMT and invasion but suppresses metastatic colonization by
inhibiting stemness
(Ocan˜a et al., 2012)
miR-200 s inhibits EMT and invasion by suppressing ZEB1/2; promotes metastatic
colonization by suppressing Sec23a-dependent secretion of metastasis
inhibitory proteins
(Brabletz and Brabletz, 2010;
Korpal et al., 2011)
miR-34 s inhibits EMT and invasion by suppressing SNAIL1 translation (Kim et al., 2011; Siemens et al., 2011)
ELF5 inhibits EMT and metastasis by suppressing SNAIL2 (Chakrabarti et al., 2012)
SIM2s inhibits EMT and invasion by suppressing SNAIL2 (Laffin et al., 2008)
KLF17 inhibits EMT by suppressing ID1 expression (Gumireddy et al., 2009)
CXCL1, IL6, IL-8,
MMP1, Fascin-1
factors involved in tumor self-seeding (Kim et al., 2009)
Survival in Circulation or Distant Organs
TrkB protects CTCs from anoikis by inducing AKT signaling (Douma et al., 2004)
Wnt2 protects CTCs from anoikis by inducing FN1 expression through
noncanonical Wnt signaling
(Yu et al., 2012)
Src promotes survival of DTCs in bone by inducing AKT-dependent survival (Zhang et al., 2009)
CXCL1/2 recruits CD11b+ myeloid cells, which produce S100A8/9 to support tumor
cell survival in metastasis and chemotherapy
(Acharyya et al., 2012)
VCAM1 recruits macrophage to support DTC survival by AKT signaling in lung
metastasis; recruits and promotes osteoclastogenesis in bone metastasis;
mediates immune evasion
(Chen et al., 2011; Lin et al., 2007;
Lu et al., 2011)
IRF7 promotes immune escape of DTCs in bone metastasis (Bidwell et al., 2012)
Metastasis Niches
S100A8a and S100A9a inflammatory proteins expressed by the lung, which recruit myeloid cells
to establish the premetastatic niche
(Hiratsuka et al., 2006, 2008)
VEGFR1a vascular endothelial growth factor receptor 1 (VEGFR1)+ bone marrow-
derived hematopoietic progenitor cells form the premetastatic niche in
lung metastasis
(Kaplan et al., 2005)
CCL5a bone marrow-derived mesenchymal progenitor cells secrete CCL5,
serving as chemoattractant to promote lung metastasis
(Karnoub et al., 2007)
TNCa Tenascin C produced by tumor or stromal cells increases tumor
stemness and promotes metastatic colonization
(Oskarsson et al., 2011)
POSTNa tumor-associated fibroblast produces Periostin to maintain cancer
stem cells by Wnt signaling
(Malanchi et al., 2012)
LOX1 recruits CD11b+ myeloid cells to form premetastatic niche (Erler et al., 2006, 2009)
Activation from Dormancy
Coco inhibits stroma-derived BMP signaling and enhancing cancer stem cell
activities
(Gao et al., 2012b)
YAP promotes cancer stem cell traits and metastatic outgrowth (Chen et al., 2012; Cordenonsi et al., 2011)
b2ARa activation of sympathetic neuron signaling increases receptor activator
of NF-kB ligand production from osteoblast and promotes the formation
of osteolytic metastasis
(Campbell et al., 2012)
aGenes are expressed by stromal cells.
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et al., 2001; Mejlvang et al., 2007; Vega et al., 2004), it has
been hypothesized that disseminating cancer cells have to revert
back to an epithelial phenotype (mesenchymal-epithelial transi-
tion [MET]) to establish a full-blown metastasis, which explains
why metastases derived from carcinomas usually resemble their
primary tumors and show an epithelial morphology (Brabletz
et al., 2001). Indeed, the notion that MET may be required for
effective colonization of DTCs in distant organs has been sup-
ported by recent experimental evidence in animal models
(Chaffer et al., 2006; Korpal et al., 2011; Tsai et al., 2012; Tsuji
et al., 2008). Thus, the current model is that tumor cells with a
high degree of epithelial-mesenchymal plasticity are most likely
to be the founder cells of metastases, because they can escape
the primary tumor in a (semi)-mesenchymal and stem-like state
and then establish a metastasis at the distant site by switching
on their epithelial characteristics (Brabletz, 2012). Among the
potential regulators of reversible EMT-MET transitions, the
negative regulations of ZEB1/2 by miR-200 s, SNAIL1 by miR-
34 s, SNAIL2 by transcriptional repressors Elf5 and SIM2s, and
multiple EMT transcription factor by FBXL14/Ppa E3 ubiquitin
ligase seems to be important (reviewed by De Craene and
Berx, 2013).
Nevertheless, there are many open questions regarding the
pathological relevance of EMT/MET switch in metastasis. At pre-
sent, it is unknown whether CTCs with a (semi)-mesenchymal
phenotype have to undergo MET in order to form metastasis
and when/how this may happen at the cascade of metastasis.
In breast cancer patients, DTCs in bone marrow express cyto-
keratins, and these epithelial DTCs are indicative of subsequent
metastatic relapse (Braun et al., 2005). Thus, it can be postulated
that MET might occur soon after extravasation of CTCs, when
they are still at the single-cell stage. A recent study also showed
that bone marrow-derived myeloid progenitor cells induce MET
at the premetastatic niche and promote metastatic colonization
(Gao et al., 2012a). To what extent the particular microenviron-
ment of the secondary site might play a role as MET inducer or
whether it is an intrinsic ability of tumor cells and whether
DTCs from different cancer subtypes and in different metastatic
organ sites have different degrees of plasticity to undergoMET is
an important subject of future investigations. Therapeutic
agents that inhibit epithelial-mesenchymal plasticity might be
effective in reducing the risk of metastasis, particularly in high-
risk timewindows, such as surgery, which can produce a shower
of DTCs.
Survival of Disseminated Tumor Cells in Secondary
Organs
Understanding the mechanisms that allow latent CTC/DTCs to
survive may be the key to the development of more effective
adjuvant therapies (Uhr and Pantel, 2011). Recent studies have
identified the AKT pathway as the major source of survival sig-
nals that can be activated by different context-dependent mech-
anisms. For example, TrkB was identified as a potent inhibitor of
anoikis in detached tumor cells through activation of AKT
(Douma et al., 2004). In breast cancer bone metastasis, the Src
gene signature was linked with late-onset bone metastasis. Src
mediates AKT regulation and the survival responses of cancer
cells to proapoptotic signals of CXCL12 and TRAIL in the bone576 Cancer Cell 23, May 13, 2013 ª2013 Elsevier Inc.microenvironment (Zhang et al., 2009). In lung metastasis,
VCAM-1 tethers tumor cells to macrophages and triggers AKT
activation in cancer cells to protect them from TRAIL-induced
apoptosis (Chen et al., 2011). VCAM-1 has also been shown to
mediate immune evasion (Lin et al., 2007), which can also regu-
late the survival of DTCs (Bidwell et al., 2012). Interestingly,
pAKT(S473) and AKT3-positive DTCs were detected in bone
marrow samples of lung cancer patients and AKT1/AKT3-
regulated proliferation, survival, migration, and epidermal growth
factor (EGF)-mediated signal transduction of these DTCs (Gra-
binski et al., 2011). The development of technology platforms
for genomic profiling of CTC/DTCs will further accelerate the
identification of clinically relevant CTC/DTC survival pathways,
as exemplified by the recent discovery ofWnt2-mediated nonca-
nonical Wnt signaling in supporting the survival and metastasis
of CTCs in pancreatic cancer (Yu et al., 2012).
An emerging concept in the study of DTCs is the potential
existence of specific organ niches to enhance the survival of
DTCs and protect them from microenvironmental or therapeutic
stress. Recent experimental findings indicate that circulating
prostate cancer cells can occupy the niches of hematopoietic
stem cells after their arrival in the bone marrow (Shiozawa
et al., 2011). These niches may keep the DTCs in a stem cell-
like state and help them survive cellular stress and chemo-
therapy. Interestingly, the hematopoietic stem cell niches are
located in the most hypoxic areas of the bone marrow, and
adaptation to hypoxia might therefore be not only a driving force
for cancer cells to leave the primary tumor but also a key process
supporting the long-term survival of DTCs and formation of
metastasis. Indeed, it has been shown that hypoxia induces
stemness of cancer cells (Conley et al., 2012), stimulates the for-
mation of premetastatic niche through recruitment of CD11b+
myeloid cells by hypoxic tumor-derived LOX-1 (Erler et al.,
2009), and promotes metastasis to bone and lung (Dunn et al.,
2009; Lu et al., 2010). The common survival requirement under
metastatic and chemotherapeutic conditions is also reflected
in the recent discovery of the CXCL1/2 mediated recruitment
of myeloid cells to produce chemokines S100A8/9 and enhance
both metastasis and chemoresistance (Acharyya et al., 2012). It
is notable that the formation of premetastatic niche in distant
organs has been consistently shown to be induced by tumor-
derived secretive factors or exosomes (Hiratsuka et al., 2006;
Kaplan et al., 2005; Peinado et al., 2012), highlighting the impor-
tance of analyzing these factors in addition to DTC/CTC analysis
in cancer patients. Such combined analysis may improve the
effectiveness of using CTC/DTC as prognostic markers or ther-
apeutic targets.
In addition to the contribution of recruited stromal cells to the
survival of DTCs, the extracellular matrix has also been recog-
nized as important components of the metastatic niche (Oskars-
son and Massague´, 2012). For example, in lung metastasis,
DTCs depends on Tenascin C (TNC), an extracellular matrix pro-
tein of stem cell niches, to maintain the metastasis-initiating
capability of disseminated tumor (Oskarsson et al., 2011). The
expression of Periostin (POSTN), another extracellular matrix
component, is induced in tumor-associated stromal fibroblast
and maintains cancer stem cells by activating Wnt signaling
(Malanchi et al., 2012). Consistent with these experimental find-
ings, positive TNC and POSTN staining were found to be an
Box 1. Open Questions about Cancer Dormancy
Do all cancer patients have dormant tumor cells?
Does EMT induce dormancy?
Do dormant cells have properties of cancer stem cells?
Are there preferred reservoirs of dormant cells (e.g., bone
marrow)?
Can host factors, such as stress or inflammation, induce or
break dormancy?
How does genetic background of the host affect dormancy of
tumor cells in particular organs?
What signaling pathways or events reactivate dormant cells?
Does the immune system play a role in dormancy?
What is the effect of current therapies on dormant cells or
dormancy?
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(Oskarsson et al., 2011; Xu et al., 2012).
Breaking out of Dormancy
Significant insights have also been obtained from experimental
and clinical studies regarding the outgrowth of DTCs or micro-
metastases, arguably the most rate-limiting step of the metasta-
tic cascade (Cameron et al., 2000). There are many theories
proposed to explain how DTCs are kept in a dormant or indolent
state before the emergence of overt metastasis, including the
lack of angiogenesis, immune surveillance, balanced prolifera-
tion and apoptosis, etc. (Uhr and Pantel, 2011). Bone marrow
has been used as a model organ to study DTCs in breast cancer
patients and repeated bone marrow sampling has revealed that
DTCs were predominantly detected as single cells, whereas
larger cell clusters indicating proliferative activity were rarely
observed (Janni et al., 2011). These findings are consistent
with previous reports demonstrating that more than 80% of
patients with breast cancer (and other solid tumors) harbor
only Ki67-negative, nonproliferating DTCs in their bone marrow
(Pantel and Brakenhoff, 2004). These observations seem to chal-
lenge the proposed new model of parallel progression (Klein,
2009), which requires cellular proliferation of DTCs as a prereq-
uisite for DTCs to progress to metastatic lesions independently
from the primary tumor. Nevertheless, the bone marrow might
have a particular dormancy-inducing environment and prolifer-
ating DTCs might exist in other secondary organs that are also
preferential sites of metastases, such as liver, lung, or brain. It
is also possible that some metastasis may arise from relatively
small percentage of DTCs that only enters proliferative phase
infrequently. Future rapid autopsy studies and genomic lineage
analysismay providemore definitive clues to this important issue
of metastatic progression (Steeg, 2008). Dormancy of DTCsmay
also be linked with the EMT state of the cells, as several previous
studies showed reduced proliferation or quiescence of cells
undergoing EMT, suggesting a requirement of MET for DTCs
to resume proliferation as metastases (Brabletz, 2012).
A better understanding of dormancy may derive from the
comparison of DTCs/CTCs in epithelial cancers with relatively
short latencies, such as lung cancer, to those in breast cancer
with long latency. Thus far, the information available in the
literature is rather limited. Comparing the proliferative activity
as measured by Ki67 immunostaining indicated that the frac-
tion of Ki67-positive solitary CTCs is higher in lung cancer as
compared to breast cancer (Hou et al., 2012; Mu¨ller et al.,
2005), which is consistent with the different latency periods of
both tumor types, and it may also explain why lung cancer
CTC counts decline rapidly during chemotherapy (Hou et al.,
2012), whereas breast cancer CTCs and DTCs appear to be
more resistant to chemotherapy (Braun et al., 2000; Mu¨ller
et al., 2005; Raimondi et al., 2011).
Another interesting comparison is colon cancer versus breast
cancer with regards to DTCs in bonemarrow. Although DTCs are
detectable in this organ at similar frequencies in both tumor
entities, overt bone metastases are rare in colon cancer but
frequent in breast cancer (Pantel et al., 1993). Thus, colon
DTCs are kept in a lifelong dormancy or they are eliminated.
Indirect evidence that the immune system might control colon
DTCs better than breast DTCs stems from phenotyping studiesof DTCs, demonstrating that expression of histocompatibility
leukocyte antigen class I molecules required for presenting
tumor antigens to T cells is less frequently downregulated in
colon DTCs than breast DTCs (Pantel et al., 1991).
Despite many outstanding questions regarding tumor dor-
mancy (Box 1), development of animal models of metastatic
dormancy has started to reveal organ-specific mechanisms of
metastatic activation from dormancy. In bone metastasis, aber-
rant expression of VCAM-1 promotes the transition from indolent
micrometastasis to overt metastasis by recruiting monocytic
osteoclast progenitors and elevating local osteoclast activity to
initiate the vicious cycle of osteolytic bone metastasis (Lu
et al., 2011). In lung metastasis, Coco, a secreted antagonist of
TGF-b ligands, induces solitary mammary carcinoma cells that
have infiltrated the lung to exit from dormancy by blocking
stroma-derived bone morphogenetic protein (BMP) signaling
and enhancing cancer stem cell characteristics (Gao et al.,
2012b). In other mouse models of dormancy, primary tumor is
therapeutically resected to recapitulate the situation in cancer
patients (Francia et al., 2011). Using such models, it is shown
that the balance of p38a/b and ERK1/2 signaling affected cancer
dormancy in breast and head and neck cancer (Sosa et al.,
2011). Moreover, dormancy signatures differ between estrogen
receptor (ER)+ and ER breast cancer, with ER+ tumors having
significantly higher dormancy signature scores, which is consis-
tent with their prolonged dormancy before resuming metastatic
growth 10 or more years after primary diagnosis (Kim et al.,
2012).
Clinical Applications
Molecular mediators of tumor dissemination, survival, and
outgrowth discussed above can be developed as biomarkers
for diagnosis and prognosis aswell as predictormarkers for ther-
apeutic agents that target these mediators (Alix-Panabie`res
et al., 2012). Sophisticated technical platforms for the detection
and molecular characterization of CTCs and DTCs have been
established (Pantel et al., 2008). Currently, CTCs are included
in more than 400 clinical trials as biomarker using various
assays (Parkinson et al., 2012). The use of CTCs as ‘‘liquid
biopsy’’ opens new avenues for genotyping/phenotyping of
(micro)metastatic cells derived from various distant sites, which
may present a more global picture than the biopsy of a singleCancer Cell 23, May 13, 2013 ª2013 Elsevier Inc. 577
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cult to obtain biopsies from multiple metastatic sites, whereas
blood samples can be easily obtained during the course of
cancer therapy, which allows a real-time monitoring of the pool
of metastatic tumor cells. Thus, validating potential therapeutic
candidate targets also through the analysis of CTCs will provide
additional information, especially with regard to actual precur-
sors of metastases in high-risk cancer patients. Interestingly,
CTCs from individual patients have shown a striking heterogene-
ity in the status of some of these target genes and their down-
stream signaling pathways (e.g., HER-2, epidermal growth factor
receptor, estrogen receptor, and androgen receptor) (Alix-
Panabie`res and Pantel, 2013), suggesting that the selection of
nonresponsive metastatic cells might be an important mecha-
nism to escape targeted therapy. Recently, several interven-
tional clinical studies based on the phenotyping of CTCs for
therapeutic targets, such as HER-2, have been started (Bidard
et al., 2012). CTCs compete with other blood-based biomarkers,
in particular, circulating cell-free tumor DNA. Analysis of circu-
lating DNA might also allow assessment of mutations relevant
to dormant, residual, or recurrent disease and may guide treat-
ment decisions in the future (Schwarzenbach et al., 2011). The
analysis of cell-free DNA in blood serum or plasma samples
offers the opportunity of easier storage and shipment compared
to the CTC approach. However, tumor DNA in blood is diluted by
variable amounts of normal DNA released by apoptotic cells, and
sophisticated methods are, therefore, required to reveal tumor-
specific genomic changes. Moreover, CTCs provide access to
intact and viable metastatic tumor cells, which offers far more
information than the analysis of degraded DNA released from
apoptotic tumor cells, including the opportunity to use cultured
CTCs for functional analyses. Thus, we believe that both
approaches—CTC and circulating tumor DNA—are comple-
mentary as liquid biopsies.
Future Directions
The convergence of animal model and clinical studies of CTCs
and DTCs has led to the development of an intellectual frame-
work to guide future research and clinical development. How-
ever, many key questions remain to be addressed to translate
better biological insights into improved therapeutics. Central
among these is the lack of understanding regarding the distin-
guishing features between the vast majority of DTC/CTCs that
are eliminated during different stages of dissemination or never
escape dormancy versus those that eventually give rise to life-
threatening metastases. Identifying the hallmark of high risk
CTC/DTCs has the potential to revolutionize the design of
clinical trials and facilitate the development of metastasis-
preventing treatments. To functionally characterize CTC/DTCs
frompatients, protocols need be developed that allow cultivation
and subsequent analysis of their tumorigenic-, stemness-,
dormancy-, and metastasis-capacities, both in vitro and in vivo.
Instead of relying on traditional trial endpoints, such as relapse-
free survival or distant metastasis-free survival, using the reduc-
tion of high-risk CTCs as a surrogate but reliable endpoint can
significantly shorten the time frame and thus reduce the cost
of clinical trials for antimetastasis adjuvant therapies. Such
improved clinical trial design may eventually lead to the approval
of treatments that are highly effective in preventing metastasis578 Cancer Cell 23, May 13, 2013 ª2013 Elsevier Inc.butmay have relatively minor effects in traditional trial endpoints,
such as reducing tumor burden or improving the survival in late-
stage patients.
Animal model studies will continue to identify potential
biomarker, gene signatures, and functional mediators for the
survival, activation, and expansion of metastasis from CTC/
DTCs. Rapid improvements in single-cell genomic analysis of
CTC/DTCs isolated from cancer patients will greatly facilitate
the identification of important functional regulators of CTC/
DTCs. Clinical validation of these new biomarkers/mediators
requires meticulous collection and molecular analysis of DTC/
CTCs throughout the course of disease progression in relevant
patient cohorts. In addition to validating genes/proteins that
can be clearly linked to the emergence of clinical metastasis,
understanding the genetic and epigenetic basis for the activation
of metastasis genes can provide valuable clues to the suspected
connections of metastatic relapse to certain physiological or
pathological conditions, such as stress, inflammation, infection,
or hormonal changes. Such clinical observations will, in turn,
inform the design of appropriate animal model experiments to
vigorously test the hypothetical links.ACKNOWLEDGMENTS
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